Press Releases
Clasado announces positive results of clinical study of Bimuno(R) for Metabolic Syndrome
Clasado, the manufacturers and suppliers of Bimuno(R), a unique trans-galactooligosaccharide prebiotic, today announces the results of a clinical study on the use of the Bimuno (B-GOS) to alter bacteria in the human gastrointestinal tract as a candidate to...
Press Releases
e-Therapeutics to Raise GBP 40 Million to Advance Lead Cancer Drug and Exploit Network Pharmacology Platform
Drug discovery and development company e-Therapeutics plc proposes to raise GBP 40 million (approximately GBP 39million net) through an issue of new ordinary shares to existing and new institutional investors. The new shares will be...
Press Releases
Labeling Considerations in the European Union and its Impact on Global Labeling Compliance
Designing a product label is a long and complex process, from the amount of time that is needed, to creating a label that is compliant with the current FDA regulations. Pharmaceutical companies are constantly managing...
Press Releases
Alpha Szenszor Inc. and Technion Announce Joint Venture in Lung Cancer Diagnostics
Alpha Szenszor Inc., a leading provider of carbon nanotube based sensors and the Technion -Israel Institute of Technology have announced a joint venture for the commercialization of advanced lung cancer diagnostics based on Volatile Organic Compound (VOC) detection...
Press Releases
GE Healthcare Works to Speed Up Fight Against Cancer
GE Healthcare’s work to accelerate cancer innovation and improve care for cancer patients reached new milestones in advanced technology. The campaign is founded on GE Healthcare’s integrated portfolio, which is uniquely positioned to drive...
Press Releases
Rhenovia Pharma recognized as the world leader in biosimulation of the central nervous system
Rhenovia Pharma, a biotechnology company created in 2007, today announces it has had its position confirmed as world leader in the field of biosimulation for research into drugs for treating diseases of the central nervous system. ...
Press Releases
Cerulean Announces First Patient Dosed in Randomized Phase 2 Study of CRLX101 in Advanced Small Cell Lung Cancer
Cerulean Pharma Inc., a leader in developing dynamically tumor-targeted nanopharmaceuticals, today announced that the first patient has been dosed in a randomized Phase 2 study of its lead candidate, CRLX101, in patients with extensive-stage small cell lung cancer...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read
















